Canephron Uno Mechanism of Action

Phyto-Urological.
Pharmacology: Pharmacodynamics: In several clinical trials Canephron lead to a fast decline of complaints within the framework of inflammatory diseases of the efferent urinary tract. The results observed during these clinical trials indicate anti-inflammatory, spasmolytic, anti-nociceptive and antibacterial effects of Canephron.
These clinical data are supplemented and supported by results of preclinical studies.
The active pharmaceutical ingredient of Canephron Uno, the drug mixture of Centaurium erythraea, Levisticum officinale, and Rosmarinus officinalis, offers a multi-facetted activity with anti-adhesive, antioxidant, anti-inflammatory, spasmolytic, and anti-nociceptive effects. In addition, antibacterial and diuretic activities are described for individual plants of the drug mixture.
Based on these effects, Canephron can reduce symptoms associated with acute lower uncomplicated urinary tract infections, such as inflammatory pain, spasms and frequent micturition. In addition, anti-adhesive effects support the elimination of bacteria from the urinary tract.
Pharmacokinetics: No pharmacokinetic data are available.
Toxicology: Preclinical safety data: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose and repeated dose toxicity, genotoxicity, toxicity to reproduction and development. Data regarding carcinogenic potential of Canephron Uno are not available.